Primary structure and expression of β2: A novel subunit of neuronal nicotinic acetylcholine receptors

A new subunit, β2, of the neuronal nicotinic receptor family has been identified. This subunit has the structural features of a non-agonist-binding subuni...

ES Deneris，J Connolly，J Boulter，... - 《Neuron》

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.

In this paper, we report on the pharmacological and functional profile of SSR180711 (1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester),...

B Biton，OE Bergis，F Galli，... - 《Neuropsychopharmacology Official Publication of the American College of Neuropsychopharmacology》

A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus

Long-term potentiation (LTP) can be modulated by a number of neurotransmitter receptors including muscarinic and GABAergic receptor types. We have found th...

BE Hunter，CMD Fiebre，RL Papke，... - 《Neuroscience Letters》

Single-Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

Varenicline is a novel and selective 4尾2 nicotinic receptor partial agonist that is under development for smoking cessation. The primary objectives of thi...

DHM Faessel，PhD，DBJ Smith，... - 《Journal of Clinical Pharmacology》

Synthesis and Pharmacological Characterization of Novel Analogues of the Nicotinic Acetylcholine Receptor Agonist (±)-UB-165

(±)-UB-165 (1) is a potent neuronal nicotinic acetylcholine receptor (nAChR) ligand, which displays functional selectivity between nAChR subtypes. Using U...

Christopher，G.，V.，... - 《Journal of Medicinal Chemistry》

Use of a nicotinic receptor agonist

The invention relates to a novel method of treatment or prophylaxis of osteoarthritis, which comprises administering to a patient in need thereof a therapeu tically effective amount of an alpha 7 nicotinic AcetylCholine recepto r agonist...

SMV Brockbank，MRC Needham，P Newham，... - WO

Use of a nicotinic receptor agonist in the treatment of dyskinesias associated with dopaminergic agent therapy

A nicotine receptor agonist, for example nicotine, may be used in the treatment of dyskinesias associated with dopaminergic agent therapy. This is especial...

M Quik，DD Monte，JW Langston

The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in ...

Monkeys that receive chronic low dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration develop deficits in spatial delayed-response...

Schneider，S J. - 《Journal of Pharmacology & Experimental Therapeutics》

Efficacy and safety of the novel αβ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a random...

Rationale α 4 β 2 Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder ( ADHD ). Obje...

G Apostol，W Abi-Saab，CJ Kratochvil，... - 《Psychopharmacology》